The firm is investing in studies that use its multiplex microarray platform to monitor lupus disease activity and traumatic brain injury response.
The Finnish firm is hoping to finalize manufacturing, validation, and commercialization of its new sample-to-result infectious disease diagnostics platform.
The firm is developing tests based on its microarray technology, which is capable of printing multiple types of biomarkers.
The company is targeting the new product at researchers who need a comprehensive, pan-ethnic, and affordable solution to genotype many samples.
Transcriptional response of pro-inflammatory and antiviral genes in the face of childhood trauma is linked to PTSD but can be mitigated.
In Science this week: new chromatin imaging approach, and more.
University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.
Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.
Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.